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ABSTRACT
Motivation: The decision to commit some or many false positives
in practice rests with the investigator. Unfortunately, not all error
control procedures perform the same. Our problem is to choose
an error control procedure to determine a P-value threshold for
identifying differentially expressed pathways in high-throughput gene
expression studies. Pathway analysis involves fewer tests than
differential gene expression analysis, on the order of a few hundred.
We discuss and compare methods for error control for pathway
analysis with gene expression data.
Results: In consideration of the variability in test results, we ﬁnd that
the widely used Benjamini and Hochberg’s (BH) false discovery rate
(FDR) analysis is less robust than alternative procedures. BH’s error
control requires a large number of hypothesis tests, a reasonable
assumption for differential gene expression analysis, though not the
case with pathway-based analysis. Therefore, we advocate through
a series of simulations and applications to real gene expression data
that researchers control the number of false positives rather than the
FDR.
Availability: Our R package, EPath.omg is available at
http://sphhp.buffalo.edu/biostat/research/software.
Contact: dlgold@buffalo.edu
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
DNA microarray technology makes possible the simultaneous
monitoring of thousands of gene expression and has been widely
applied to detect gene activity changes in many areas of biomedical
research. Traditionally, the microarray data were analyzed using
a gene by gene strategy, which focused on individual gene’s
expression change across contrasting conditions. This gene-based
approach, while useful to identify the most signiﬁcant changes,
couldoftenneglecttheinformationingenes’jointdistribution.From
the viewpoint of biology, the biological mechanisms underlying
gene activity change are generally the result of interactions between
multiple genes in a modular pathway, with most of its members
characterizedbysubtleactivechanges.Suchmodestbutconsistently
coordinate effects are difﬁcult to be identiﬁed by gene expression
analysis.
∗To whom correspondence should be addressed.
To overcome the limitations of the gene expression analysis,
pathway-basedenrichmentmethodshavebeendevelopedtoidentify
changes in the collections of genes, thought to be involved in the
same underlying biological process (i.e. pathway), thus allowing
the incorporation and weighting of prior biological knowledge
into microarray analysis. The earliest pathway-based approaches
followed from Fisher’s test, comparing the distributions counts
of differentially expressed genes (DEGs) in each pathway with
the overall distribution (Khatri and Drghici, 2005). Other methods
include parametric analysis of gene set enrichment (PAGE) (Kim
and Volsky, 2005), which attempts to model the changes in DEGs
belonging to pathways by a parametric model. The more popular
pathway analysis employ stringent permutation-based methods,
attempting to account for gene–gene correlation. Examples of these
are gene set enrichment analysis (GSEA) (Subramanian, 2005) and
gene set analysis (GSA) (Efron and Tibshirani, 2007). In GSEA,
all of the genes are ﬁrst ranked, by their signiﬁcance in terms
of differential expression, and then, the rankings are tested, to
determine whether a particular predeﬁned collection of genes is
randomly distributed throughout the ranked list, or enriched at
either the top or bottom of the list (Efron and Tibshirani, 2007;
Subramanian, 2005). GSA employs the max–mean statistic, as a
measureofsigniﬁcanceforeachpathway,whatEfronandTibshirani
claim is more powerful and discriminatory approach, and uses a
permutation-based approach to determine the null distribution.
One of the critical assumptions underlying the pathway-based
strategy is the availability of a collection of well-curated pathways.
These can be obtained through existing annotation information
such as that provided by the Kyoto Encyclopedia of Genes and
Genomes (KEGG) (Kanehisa and Goto, 2000). KEGG is one of
the most complete and academically available pathway databases,
whose latest release includes about 210 curated non-redundant
pathways in human. Although it is possible to create more gene
sets in silico (e.g. through chromosome neighborhoods, expression
neighborhoods and regulatory motif sharing, etc.), the increasing
functional heterogeneity associated with such less-curated gene
sets make them difﬁcult for subsequent interpretation in terms of
biological mechanism. As a result, many published pathway-based
application (Jimeno et al., 2008; Pangas et al., 2008; Setlur et al.,
2007; Xu et al., 2007) or evaluation (Liu et al., 2007; Song and
Black, 2008) in microarray data analysis used a couple of hundred
well-curatednon-redundantpathwaysmergedfromKEGGandother
public annotation systems like Biocarta and/or Gene Ontology
(GO). Although KEGG is not freely available to all users, our
arguments regarding error control for pathway analysis apply to
similar databases used to construct the pathways.
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Both gene- and pathway-based analysis deal with the challenge
of multiple testing error control (i.e. multiplicity correction ). Three
universal error control strategies are applied in the microarray
analysis literature, controlling the false discovery rate (FDR), false
positive count or simply choosing the top K from a ranked list.
The FDR-based method of Benjamini and Hochberg (1995) has
been widely applied in the analysis of gene expression microarray
analysis, and is also a popular choice in pathway-based microarray
analysis. However, the size of multiplicity is quantitatively different
between them. For example, the latest human U133plus 2.0 array
contains ∼54000 probe sets targeting at ∼38000 human genes,
including ∼37000 probe sets for ∼18000 curated refseq genes. On
the other hand, typically much fewer than 500 canonical pathways
(e.g. from KEGG, Biocarta or GO databases, etc.) are available
for pathway-based approaches, and less are used after excluding
pathways with less than a certain number of genes expressed in the
chips. The shift from massive multiplicity in the gene expression
approach, to reduced multiplicity in pathway-based methods raises
interesting questions about the accuracy of FDR-based procedures
in pathway studies. We addressed this issue here by ﬁrst brieﬂy
reviewing the terminology of multiple testing.
1.1 Family-wise error rate
Suppose that 10000 hypothesis tests are performed, each controlled
at the 0.05 level. If all null hypotheses are true, on average you can
expect 500 false positives, far too many false leads in practice. Carlo
E. Bonferroni (1892–1960) suggested controlling the probability of
at least one false positive, what he called the family-wise error rate
(FWER). The FWER procedure, given N hypothesis tests, controls
the FWER at level α with P-value threshold α/N. Notice that the
Bonferroni threshold becomes more stringent, i.e. conservative, as
the number of tests N increases, diminishing power for microarray
analysis. For this reason new methods of error control were devised.
1.2 FDR analysis
Multiple statistical testing procedures began to be reexamined
in the early 1990s, with the advent of high-throughput genomic
technologies, in light of microarray analysis. Benjamini and
Hochberg (BH) proposed controlling the FDR, or the expected rate
of false test positives (Benjamini and Hochberg, 1995). In the BH
multiple testing procedure, the FDR is controlled by the following
scheme:
(1) Let p(1)<···<p(N) denote the N ordered P-values.
(2) Let ˆ t=p(k) for the largest k such that p(k)≤α∗k/N
(3) Reject all null hypothesis H0i for which pi≤ˆ t.
BH prove that if the above procedure is applied, then FDR≤α.
Storey (2002) showed, for P-value threshold t,
FDR(t)=
(1−π)t
(1−π)t+πF(t)
(1)
where π is the probability that an alternative hypothesis is true,
and F(t) is the distribution of P-values given the alternative. FDR
performance has been evaluated for gene detection given a variety
of scenarios, for examples, in the presence of gene–gene correlation
(Benjamini and Yekutieli, 2001; Shao and Tseng, 2007). FDR
analysis does not control what Genovese andWasserman (2004) call
therealizedFDR(rFDR),thenumberoffalserejectionsV dividedby
thenumberofrejectionsR(assumingatleastonerejection),whichin
fact, can be quite variable, see our Supplementary Materials. Since
researchers do not have knowledge of the truly DEGs, the rFDR
is unknown in a real experiment. Several of the multiple testing
procedures (MTPs) thus try to control the expectation of the rFDR,
(often confusingly abbreviated as FDR).
BH control is achieved only in large sample sense, as BH
showed that as the number of tests goes to inﬁnity, the expected
rate of false positives is bounded above. BH’s result controls the
FDR≤(1−π)α≤α as N →∞, through π, the percentage of true
(and in practice unknown) positives. In other words, a desired FDR
control of 10% might yield less power than hoped for inversely
to π (Storey, 2002).
1.3 Controlling the number of false positives
Lehman and Romano (2005) proposed controlling against at least
K false positives, what he called K FWER (KFWER) with P-value
threshold α·K/N. Like the FWER control, the KFWER P-value
threshold becomes more stringent as the number of tests N becomes
larger. We consider the K binomial method, KBIN (Miecznikowski
et al., 2009), to control KFWER. Like Lehman and Romano (2005),
KBIN also controls the probability of at least K false positives,
although for our purposes can achieve greater power. The KBIN
procedure follows from basic probability concepts, to control the
probability that the number of false positives V is not larger than
k to be α, that is,
Pr(V >k)≤α
where V is the number of false positives, assumed to follow a
Binomial distribution, with k deﬁned by the user. The procedure
rejects all hypotheses with P-values less than αcut, where αcut is the
value of α that solves the equation below
F(N,k,α)≥1−β
where F is the cumulative density function for a Binomial
distribution with N trials and probability of success α and β is
usually chosen to be large, e.g. 0.95. KFWER provides a convenient
approximation for choosing αcut in the case that N is large.
In contrast, KBIN is determined before the data are observed,
ratherthanestimatedfromdata.GiventhewaytheP-valuethreshold
is estimated, when the number of false positives exceeds the desired
bound K, it tends not to be much larger, see our Supplementary
Materials. One might also consider selecting the top K pathways,
i.e. with the smallest P-values. We call this method TopK. TopK
and KBIN are less variable than BH for pathway analysis, although
they have their own drawbacks such as lacking meaningful control
and interpretation. For example, suppose for KBIN K = 5, and three
pathways are discovered, while in another case 20 pathways are
discovered. Clearly the latter seems to lend better interpretation.
In practice, it is impossible to predict how many pathways will be
detected with KBIN.
2 METHODS
2.1 Simulation studies
The theoretical results of BH’s FDR control hinge on a large number of
tests. This begs the question, when is it inappropriate to report α-control
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of FDR? In order to answer this question, we illustrate the performance
of BH’s FDR analysis simulating data under two scenarios. In Simulation
1, we have a relatively large number of signiﬁcant tests, each with small
effects. In Simulation 2, there are fewer relative signiﬁcant tests, but when
signiﬁcant, the effects are larger. The underlying P-value distributions in our
simulations are described at length in the Appendix A. In both simulations,
we let the number of tests N =250. Simulating from a model provides us
with well-deﬁned functions, FDR(t) and rFDR(t), of the P-value threshold t.
Wecomparethediscriminationperformanceofourcandidates:BH,KBIN
and TopK, for Simulations 1 and 2, each of the 10000 iterations. The true
positivedetectionrate(PDR)andthetruenegativedetectionrate(NDR)were
measured in each simulation as the mean number of positives and negatives,
detected at a given threshold. While it is not possible to compare BH, KBIN
and TopK directly since they control different quantities, there exists, for
example, a pair (α,K) yielding near identical average PDR performance for
both BH and KBIN. Therefore, we consider a range of criteria: for FDR, we
let α ranged from 0.01 to 0.99, KBIN K ranges from 0 to 250 and TopK, K
ranges from 1 to 250. We use 20 and 50 values for each method in either
simulation, respectively. We compare both the relative PDR/NDR mean and
standard deviation (SD) by method across all 10000 simulated datasets.
2.2 Gene expression data
Weperformpathwayanalysisonasubsetofthesamplesinthecervicalcancer
study of Scotto et al. (2008), contrasting pathways in normal (24 cases) from
cervical cancer (33 cases) specimens, on U133AAffymetrix arrays. Unlike
simulated data, real data pathway analysis can be inﬂuenced by gene–gene
correlation. To this end we favor permutation-based methods that attempt
to account for gene–gene correlation yielding more robust results. PAGE
and expression analysis systematic explorer (EASE), for example, ignore
gene–gene correlation in determining P-values (Hosack et al., 2003; Kim
and Volsky, 2005).
We compare the performance of KBIN and BH, for various levels of
control, given the nominal P-values of GSA (Efron and Tibshirani, 2007)
and GSEA(Subramanian, 2005). We modiﬁed the original restandardization
step in GSA, rescaling by the max–mean scores by the median absolute
deviation (MAD). The MAD estimator is more robust to outliers, i.e.
signiﬁcantmax–meanstatisticsandthusyieldsnominalP-valuedistributions
more consistent with the underlying assumptions of BH. In the authors’
experience, an abundance of positive, or negative, max–mean scores, can
inﬂatetheSDestimateforrestandardization,andpotentiallybiasthenominal
P-value distribution. This issue is easily rectiﬁed with the more robust
MAD estimator. Otherwise, we did not alter GSA, nor seek improvements
or modiﬁcations. For GSEA, we perform the kolmogorov-smirnov (KS)
test, i.e. setting P=0 in the original algorithm, and applied BH and KBIN
to the nominal P-values (i.e. we did not apply GSEA’s multiple testing
procedure, which we comment on below). We repeat analysis on 100 boot
strapped versions of the data (Efron and Tibshirani, 1994), to contrast the
distributions on the results, in particular the (random) number of pathways
discovered as enriched for each criterion and method. We repeated the above
analysis comparing gene expression in smokers versus non-smokers, from
the Spira et al. study, on U133AAffymetrix arrays Spira et al. (2004), and
differences in acute megakaryoblastic leukemia (AMKL) with and without
down syndrome status (Bourquin et al., 2006).
3 RESULTS
3.1 Simulation studies
3.1.1 FDR and rFDR There is a discordance between the FDR
and rFDR for pathway analysis. In Figure 1, the variability in the
rFDR for both Simulations 1 and 2 is extreme, and appears to be
quitediscordantfromtheFDRcontrollevel.Researchersshouldﬁnd
this troubling. The frequency histogram of ˆ t, shows the sampling
variability in the decision rule to reject. This variability can better
be illustrated though the FDR function, as function of ˆ t, not to
be confused with the desired FDR level of control level which is
a constant. In the results of Simulation 1, there is a spike in the
probability that the FDR(ˆ t) = 0, and a long right tail. Similar results
are observed for Simulation 2. This indicates that the method has
a tendency to be overly conservative for N = 250 tests. Summary
statistics for each simulation are listed in Table 1 of Supplementary
Materials, including results for BH control at α=0.01. Note that for
N =5000,availableintheSupplementaryMaterials,thediscordance
between FDR and rFDR disappears.
3.1.2 Comparison of error control procedures Amethod that can
achieve, say, on average higher PDR than all other methods, over
the range of NDR, would be attractive, although variability can play
a role. In Figure 2, average PDR, over 10000 simulations, improves
as the threshold becomes more liberal, i.e. leading to negative
consequencesfortheaverageNDR.Notice,therelativeperformance
of all three methods is on average the same, yet the SD in PDR and
NDR,measuredoverall10000simulateddatasets,tendstobehigher
forBHthanKBINandTopK.ThetrendintheSDfallsastheaverage
PDRorNDRimprove,expectedsinceatP-valuethresholdextremes
there are fewer relative misclassiﬁcations, respectively. Practically
speaking, this means that KBIN and TopK provide typically less
variable results than BH, while delivering the overall expected
beneﬁt of error control.
3.2 Application to real data
Since BH and KBIN control different things, the two are not directly
comparable. Hence, for a multitude of control levels, we use the
meannumberofpathwaysdetected,estimatedbybootstrapanalysis,
as the equating metric between BH and KBIN.This allows sufﬁcient
comparison of the bootstrap variability in the number of pathways
detected, for different control levels between procedures, that on
average yield similar results. For any level of control, the method
that is most consistent is preferred. Below we list selected results for
each dataset, see our Supplementary Materials for complete results.
3.2.1 Cervical cancer We found similar results in BH and KBIN
for conservative control, the relative variability in BH increased as
the control was allowed to be more liberal. For example, BH’s with
1% FDR control and KBIN with K = 1 yield mean (SD) counts of
discovered pathways across bootstrap versions of the dataset of 6.8
(2.4). For GSA and GSEA, respectively, BH controlled at the 10%
FDR level, yields mean (SD) counts of 10.26 (3.29) and 5.79 (2.6),
and KBIN with K = 2 yields 9.85 (2.59) and 6.36 (2.11). The mean
(SD) of counts for FDR control at 20% are 13.26 (3.33) and 8.77
(4.24), while KBIN with K = 6 yields 13.91 (2.35) and 8.88 (2.69),
see Table 1.
3.2.2 Smoking-associated changes in gene expression In this
dataset, similar to what we found in the Cervical cancer data, we
noticed that GSAtended to yield more pathways than GSEA. Given
theresultsofGSA,BHcontrolledat10%and20%FDRyieldsmean
(SD) counts of 5.41 (4.19) and 7.41 (5.6) discovered pathways. In
contrast, KBIN with K=2 yields 5.11 (3.18) and K=3, 7.15 (3.95)
counts, respectively. Given the P-values from GSEA, FDR control
of 20% yields 1.65 (3.03) counts compared with KBIN with K =2
of 1.44 (1.62) counts, see Table 2.
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Fig. 1. Simulation of sampling variability in FDR and rFDR top row Simulation 1, bottom row Simulation 2, for FDR control level of 10%.
Fig. 2. Comparison of BH (solid), KBIN (dash) and TopK (dot): top row Simulation 1, bottom row Simulation 2.
3.2.3 Down Syndrome-associated changes in AMKL As shown
in Table 3, KBIN shows >4-fold less variability than BH in this
dataset, for on average comparable results. Fewer pathways were
detected with BH, for both GSAand GSEA, over a range of control
levels, than KBIN. Controlling at 35% FDR, the mean count of
detectedpathwaysis1.06(2.47)and1.15(2.29),respectively.KBIN,
K=2,yieldsameancountof1.02(1.14)pathwaysforGSAand1.25
(1.14) pathways for GSEA.
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Table 1. Mean and SD of counts of cervical cancer pathways detected
GSA
α 0.01 0.05 0.1 0.15 0.2 0.25 0.3
BH Mean 6.8 8.48 10.26 11.56 13.26 14.72 16.53
SD 2.4 3.27 3.29 3.38 3.33 3.76 4.22
K 1 23 4689
KBIN Mean 6.8 9.85 10.83 12.27 13.91 15.95 16.57
SD 2.4 2.59 2.49 2.4 2.35 2.55 2.61
GSEA
α 0.01 0.05 0.1 0.15 0.2 0.25 0.3
BH Mean 3.73 4.19 5.67 7.09 8.74 10.64 12.21
SD 1.57 2.29 2.7 3.45 4.34 5.41 6.17
K 123 4 6 8 9
KBIN Mean 3.73 6.27 7.11 8.86 11.12 13.94 14.65
SD 1.57 2.18 2.5 2.78 3.08 3.44 3.54
Table 2. Mean and SD of counts of smoking-related pathways detected
GSA
α 0.01 0.05 0.1 0.15 0.2 0.25 0.3
BH Mean 3.75 4.28 5.41 5.41 7.41 9.08 10
SD 2.45 3.29 4.19 4.19 5.6 6.57 7.22
K 123 4 6 8 9
KBIN Mean 3.75 5.11 7.15 7.95 10.01 11.72 12.64
SD 2.45 3.18 3.95 4.19 4.82 5.19 5.32
GSEA
α 0.01 0.05 0.1 0.15 0.2 0.25 0.3
BH Mean 0.82 0.86 0.93 1.33 1.65 2.8 3.27
SD 1.12 1.36 1.68 2.07 3.03 4.23 4.68
K 123 46 8 9
KBIN Mean 0.82 1.44 3.04 3.59 5.74 7.55 8.79
SD 1.12 1.62 2.31 2.32 3.26 3.8 4.05
4 DISCUSSION AND CONCLUSION
While there are now many methods for conducting pathway
analysis (Huang et al., 2008), relatively little is discussed about
how to control the error for pathway discovery. We recognize
that in practice, a variety and/or composite of error control
methods are applied. For our purposes, we were concerned with
comparingthesoleperformanceofrepresentativemethodsincluding
BH, KBIN and TopK. BH is widely applied, partly because it
requires less computation than competing FDR analysis, offering
a simple interpretation, i.e. FDR≤α. In contrast, KBIN bounds
the probability of committing more than a speciﬁed number of
false positives. While KFWER and KBIN offer control of the false
positive count, KBIN is more powerful and, thus preferred. Our
results demonstrate the sole performance of individual method,
which serves for future study of consensus approaches.
Table 3. Mean and SD of counts of AMKL pathways detected
GSA
α 0.01 0.05 0.1 0.15 0.2 0.25 0.3
BH Mean 0.28 0.28 0.35 0.36 0.56 0.56 0.84
SD 0.6 0.6 0.8 0.82 1.27 1.27 1.79
K 123 4689
KBIN Mean 0.28 1.02 1.43 2.26 3.33 5.1 5.41
SD 0.6 1.14 1.38 1.81 2.26 2.88 3.03
GSEA
α 0.01 0.05 0.1 0.15 0.2 0.25 0.3
BH Mean 0.33 0.33 0.33 0.37 0.67 0.68 0.99
SD 0.65 0.65 0.65 0.75 1.26 1.29 1.84
K 123 4689
KBIN Mean 0.33 1.25 1.64 2.51 3.72 5.2 5.62
SD 0.65 1.14 1.37 1.67 2.14 2.54 2.6
We found BH more variable than KBIN or TopK for pathway
analysis, both in simulation and with three real datasets, from
independent labs, addressing different hypotheses. The reason for
the variability in BH’s FDR analysis is that ˆ t is estimated from
data, and therefore suffers from sampling variation. Note, when the
numberoftestsismuchgreaterthanN =250tests,sayN ≥5000,the
variability in the sampling distribution of the rFDR is considerably
reduced,seeSupplementaryMaterials.FDRcontrolprocedures,that
attempt to estimate the distribution of the p-values will suffer from
sampling variability as we demonstrated.
If one expects to obtain, for example, a list of 10–20 candidate
pathways, a liberal FDR control of 30% provides reasonable costs.
In our applications, KBIN yields, with comparable results to that of
BH’s FDR control of 30%, between a 2.25- and 4-fold reduction in
variability in the count of detected pathways across three bootstrap
analysisofindependentdatasets.WhileBH’serrorcontrolprocedure
offers interpretation for gene discovery, interpretation is lacking
for pathways, due to the variability in the rFDR. We prefer KBIN
for pathway analysis, yielding less variability than BH, and better
interpretation than TopK.
We encourage investigators to consider the relative costs in
selecting an error control procedure, taking into account N, the
number of hypothesis tests. Gene annotations will no doubt evolve,
eventuallycallingfornewmethodsforpathwayanalysis.Procedures
that attempt to control error should be examined in the light of what
they are controlling and how accurately they control it given what
is known about the experiments.
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A APPENDIX
A1 Simulations: two-component mixture model
A useful and widely adopted model considered for FDR analysis is
the two-component P-value mixture model, pi∼(1−π)u+πf, for
i=1,...,N pathways. The ﬁrst component of the mixture follows a
uniform distribution, the distribution of P-values when the null is
true.Thesecondcomponentf isassumedtobeconcave.Themixture
weight π, the percentage of pathways that are enriched, is generally
assumed to be small. For any P-value threshold t, the FDR(t)=
(1−π)t/((1−π)t+πF(t)) for cumulative distribution function of
the P-values for which the alternative is true, F(t)=
 t
0 f(t)dt. The
realized FDR, the rate of false positives (FPs), rather than expected
rate, follows the distribution of η1/(η1+η2), if η1+η2>0, for η1 ∼
Binomial(N,(1−π)t) and η2 ∼Binomial(N,πF(t)), i.e. distributed
as Binomial random variables with N trials and respective success
probabilities. Otherwise, the rFDR is equal to zero if no discoveries
are made. This is a complicated distribution, often easier to simulate
than determine analytically.
In the ﬁrst simulation, we let N =250, π =0.20 and the
distribution of P-values under the alternative hypothesis, i.e. for
enriched pathways, follows a beta distribution with parameters 1/2
and2.Thissimulationcorrespondstothecasewheremanypathways
are enriched, although, the differential effects in gene expression
underlying enrichment are moderate. Since the true FDR function
is known, we ﬁnd that FDR (0.001734105) = 10%. In our second
simulation, we let π =0.05, and the distribution of P-values for
enriched pathways follows a beta distribution with parameters 0.1
and 10, corresponding to the situation of few enriched pathways,
with large effect sizes in differential gene expression underlying the
enrichment. In this case, we ﬁnd that FDR (0.004468064) = 10%.
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